EMA’s transformative treatments of 2020
In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.
List view / Grid view
In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.
Lumasiran, an investigational drug to treat primary hyperoxaluria type 1, has met its endpoints in clinical trials.